{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:35:48Z","timestamp":1789756548194,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T00:00:00Z","timestamp":1409616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s40262-014-0175-9","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T04:52:29Z","timestamp":1409547149000},"page":"1033-1044","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetics, Pharmacodynamics, and Tolerability of Single Ascending Doses of RCT-18 in Chinese Patients with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"53","author":[{"given":"Xia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,2]]},"reference":[{"issue":"3","key":"175_CR1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","volume":"4","author":"Y Alamanos","year":"2005","unstructured":"Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130\u20136.","journal-title":"Autoimmun Rev"},{"key":"175_CR2","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/ar2368","volume":"10","author":"QY Zeng","year":"2008","unstructured":"Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther. 2008;10:R17.","journal-title":"Arthritis Res Ther"},{"key":"175_CR3","unstructured":"Stoddard S, Jans L, Ripple J, et al. Chartbook on work and disability in the United States, 1998: an Info Use report. US National Institute on Disability and Rehabilitation Research. http:\/\/www.infouse.com\/disabilitydata\/workdisability\/3_2.php ."},{"issue":"45","key":"175_CR4","doi-asserted-by":"crossref","first-page":"35478","DOI":"10.1074\/jbc.M005224200","volume":"275","author":"Y Wu","year":"2000","unstructured":"Wu Y, Bressette D, Carrell JA, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem. 2000;275(45):35478\u201385.","journal-title":"J Biol Chem"},{"issue":"3","key":"175_CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejphar.2011.01.002","volume":"654","author":"Y Liu","year":"2011","unstructured":"Liu Y, Zhang L, Wu Y, et al. Therapeutic effects of TACI-Ig on collagen-induced arthritis by regulating T and B lymphocytes function in DBA\/1mice. Eur J Pharmacol. 2011;654(3):304\u201314.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"175_CR6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2249.2010.04293.x","volume":"163","author":"D Wang","year":"2011","unstructured":"Wang D, Chang Y, Wu Y, et al. Therapeutic effects of TACI-Ig on rat with adjuvant arthritis. Clin Exp Immunol. 2011;163(2):225\u201334.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"175_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.23178","volume":"58","author":"PP Tak","year":"2008","unstructured":"Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61\u201372.","journal-title":"Arthritis Rheum"},{"key":"175_CR8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/0091270008315312","volume":"48","author":"I Nestorov","year":"2008","unstructured":"Nestorov I, Munafo A, Papasouliotis O, et al. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol. 2008;48:406\u201317.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"175_CR9","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/art.30372","volume":"63","author":"RF Vollenhoven van","year":"2011","unstructured":"van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1782\u201392.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"175_CR10","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.30373","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011;63(7):1793\u2013803.","journal-title":"Arthritis Rheum"},{"key":"175_CR11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727\u201335.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"175_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3899\/jrheum.120886","volume":"40","author":"W Stohl","year":"2013","unstructured":"Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol. 2013;40(5):579\u201389.","journal-title":"J Rheumatol"},{"issue":"5","key":"175_CR13","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2506","volume":"10","author":"R Furie","year":"2008","unstructured":"Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonalantibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.","journal-title":"Arthritis Res Ther."},{"key":"175_CR14","doi-asserted-by":"crossref","unstructured":"Nestorov I, Papasouliotis O, Pena Rossi C, et al. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci. 2010;99:524\u201338.","DOI":"10.1002\/jps.21839"},{"key":"175_CR15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"175_CR16","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI38010","volume":"119","author":"MP Cancro","year":"2009","unstructured":"Cancro MP, D\u2019Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119:1066\u201373.","journal-title":"J Clin Invest"},{"key":"175_CR17","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.4049\/jimmunol.176.11.6405","volume":"176","author":"JP Miller","year":"2006","unstructured":"Miller JP, Stadanlick JE, Cancro MP. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol. 2006;176:6405\u201310.","journal-title":"J Immunol"},{"issue":"3","key":"175_CR18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920021503140412212905","volume":"15","author":"S Shi","year":"2014","unstructured":"Shi S. Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014;15(3):271\u201390.","journal-title":"Curr Drug Metab"},{"key":"175_CR19","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2506","volume":"10","author":"R Furie","year":"2008","unstructured":"Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R109.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"175_CR20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s11095-005-5882-3","volume":"22","author":"M Danhof","year":"2005","unstructured":"Danhof M, Alvan G, Dahl SG, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: a new classification of biomarkers. Pharm Res. 2005;22(9):1432\u20137.","journal-title":"Pharm Res"},{"key":"175_CR21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00228-007-0311-7","volume":"63","author":"A Munafo","year":"2007","unstructured":"Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol. 2007;63:647\u201356.","journal-title":"Eur J Clin Pharmacol"},{"key":"175_CR22","doi-asserted-by":"crossref","unstructured":"Westra J, van Assen S, Wilting KR, et al. Rituximab impairs IgM and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014. doi: 10.1111\/cei.12390 (Epub ahead of print).","DOI":"10.1111\/cei.12390"},{"issue":"10","key":"175_CR23","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1136\/ard.2011.150219","volume":"70","author":"M Bombardieri","year":"2011","unstructured":"Bombardieri M, Kam NW, Brentano F, et al. A BAFF\/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann Rheum Dis. 2011;70(10):1857\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"175_CR24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3899\/jrheum.091432","volume":"37","author":"D Jawaheer","year":"2010","unstructured":"Jawaheer D, Maranian P, Park G, et al. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol. 2010;37(12):2475\u201385.","journal-title":"J Rheumatol"},{"issue":"1","key":"175_CR25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3899\/jrheum.110548","volume":"39","author":"D Jawaheer","year":"2012","unstructured":"Jawaheer D, Olsen J, Hetland ML. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis: results from the DANBIO registry. J Rheumatol. 2012;39(1):46\u201353.","journal-title":"J Rheumatol"},{"key":"175_CR26","doi-asserted-by":"crossref","unstructured":"Lee J, Mason R, Martin L, Barnabe C. Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study. Rheumatol Int. 2014 (Epub ahead of print).","DOI":"10.1007\/s00296-014-2999-x"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0175-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0175-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T10:41:27Z","timestamp":1565779287000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0175-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,2]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0175-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,2]]}}}